The global Artificial Intelligence (AI) in Biotechnology market size is predicted to grow from US$ 4064 million in 2025 to US$ 13570 million in 2031; it is expected to grow at a CAGR of 22.3% from 2025 to 2031.

AI in biotech is critical for boosting invention in labs and throughout a medicine's or chemical compound's lifecycle. AI-based tools and applications aid in the development of molecule structures per the target market. Machine learning, a subset of artificial intelligence, aids in estimating combinations and permutations of different compounds to determine the best combination without the need for manual experiments in the lab. Artificial intelligence's application in biotech brings about innovations that aid predictive modeling to forecast market demand for a specific drug or chemical. AI in Biotech can also assist in the smart distribution of raw materials needed by the biotech sector via cloud computing.

Key Features:

• Market shares
• Growth opportunities
• Regional analysis

Segmentation by Type:

• Hardware
• Software and Services

Segmentation by Application:

• Agriculture Biotechnology
• Medical Biotechnology
• Animal Biotechnology
• Industrial Biotechnology
• Others

Market by Region:

1. Americas
   • United States
   • Canada
   • Mexico
   • Brazil
2. APAC
   • China
   • Japan
   • Korea
   • Southeast Asia
   • India
   • Australia
3. Europe
   • Germany
   • France
   • UK
   • Italy
   • Russia
4. Middle East & Africa
   • Egypt
   • South Africa
   • Israel
   • Turkey
   • GCC Countries

Company Coverage:

• AstraZeneca
• Abbott Laboratories
• Amgen, Inc.
• Atomwise
• Biogen
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc
• Johnson & Johnson Services, Inc.
• Pfizer, Inc.
• Merck KGaA
• Novo Nordisk A/S
• Novartis AG
• Sanofi

Key Questions Addressed in this Report: